Amphastar Pharmaceuticals (AMPH) to Release Quarterly Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Amphastar Pharmaceuticals to post earnings of $0.97 per share and revenue of $190.48 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Amphastar Pharmaceuticals Stock Up 0.7%

NASDAQ:AMPH opened at $28.66 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.12 and a quick ratio of 2.21. The company’s fifty day moving average price is $27.14 and its 200-day moving average price is $26.85. Amphastar Pharmaceuticals has a 1-year low of $20.39 and a 1-year high of $32.69. The firm has a market capitalization of $1.32 billion, a P/E ratio of 12.68, a PEG ratio of 5.19 and a beta of 0.88.

Wall Street Analysts Forecast Growth

AMPH has been the topic of several analyst reports. Needham & Company LLC cut their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Zacks Research downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Finally, Barclays started coverage on Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price target for the company. Two research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $31.00.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 9,787 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total value of $256,419.40. Following the sale, the executive vice president directly owned 138,043 shares of the company’s stock, valued at approximately $3,616,726.60. This trade represents a 6.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total value of $113,250.90. Following the completion of the sale, the director owned 35,183 shares of the company’s stock, valued at $953,459.30. This trade represents a 10.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 18,129 shares of company stock worth $477,176 in the last 90 days. Corporate insiders own 27.50% of the company’s stock.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Rafferty Asset Management LLC purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth $206,000. Commonwealth Equity Services LLC lifted its holdings in Amphastar Pharmaceuticals by 11.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,742 shares of the company’s stock valued at $234,000 after purchasing an additional 882 shares in the last quarter. Janney Montgomery Scott LLC grew its position in shares of Amphastar Pharmaceuticals by 6.2% in the fourth quarter. Janney Montgomery Scott LLC now owns 14,230 shares of the company’s stock valued at $381,000 after purchasing an additional 825 shares during the period. Franklin Resources Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $254,000. Finally, PDT Partners LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth about $336,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.